Breaking News Instant updates and real-time market news.

NVS

Novartis

$85.88

1.1 (1.30%)

, LPCN

Lipocine

$1.63

0.07 (4.49%)

04:55
01/06/19
01/06
04:55
01/06/19
04:55

Focus Medical Communications to hold a conference

NASH-TAG Conference 2019 will be held in Park City, Utah on January 3-6.

NVS

Novartis

$85.88

1.1 (1.30%)

LPCN

Lipocine

$1.63

0.07 (4.49%)

NVO

Novo Nordisk

$47.35

0.13 (0.28%)

  • 06

    Jan

  • 06

    Jan

  • 06

    Jan

  • 06

    Jan

  • 07

    Jan

  • 07

    Jan

NVS Novartis
$85.88

1.1 (1.30%)

12/11/18
JEFF
12/11/18
INITIATION
Target $105
JEFF
Buy
Novartis assumed with a Buy at Jefferies
Jefferies analyst Peter Welford assumed coverage of GNovartis with a Buy rating and $105 price target. The analyst is positive on the European large-cap Pharma space "as it enters a period of sustained earnings momentum."
01/02/19
JPMS
01/02/19
DOWNGRADE
JPMS
Underweight
Novartis downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser downgraded Novartis to Underweight with a price target of CHF 89. The analyst has concerns over the company's pipeline and believes the shares are close to fair value.
12/20/18
WELS
12/20/18
NO CHANGE
WELS
Drug industry facing 'brave new world' with drug price scrutiny, says Wells
After Reuters reported that nearly 30 drugmakers are planning to raise the prices of their medicines in the U.S. starting in January, including Novartis (NVS), Bayer (BAYRY), GlaxoSmithKline (GSK), Amgen (AMGN), AstraZeneca (AZN), Biogen (BIIB) and Allergan (AGN), Wells Fargo analyst David Maris told investors in a research note that he has repeatedly highlighted how the practice of drug price increases is a risk for the industry, and believes the latest actions by these manufacturers will be "front and center" for the Trump administration heading towards an election year. He also expects to see increased political and legislative pressure on drug prices as Democrats take over the House in January, and continues to believe that the drug industry is facing a "brave new world" with greater scrutiny of drug prices, lower price increases vs. historical levels, and as a result potentially lower profit margins.
12/18/18
COWN
12/18/18
NO CHANGE
COWN
Outperform
Cowen sees Sandoz deal as reinforcing Tilray's competitive positioning
Tilray's (TLRY) expanded global partnership with Novartis (NVS) division Sandoz can not only help expand its reach with pharmacists, physicians and distributors, it can also help Tilray capture early share in new medical cannabis markets as they come online, Cowen analyst Vivien Azer tells investors in a research note. Further, the analyst believes the partnership also helps legitimize cannabis in international markets, which could help influence countries considering medical cannabis legalization. Azer estimates international will represent 15% of Tilray's revenue in fiscal 2020 and 22% in fiscal 2021. Not only does the deal allow Tilray to expand geographic reach, but also to grow at scale, says Azer. And most notably, the Sandoz deal reinforces Tilray's competitive positioning, adds the analyst, who keeps an Outperform rating on the shares with a $150 price target. The stock in morning trading is up 9%, or $5.98, to $71.87.
LPCN Lipocine
$1.63

0.07 (4.49%)

03/29/18
GHSC
03/29/18
INITIATION
Target $10
GHSC
Buy
Lipocine initiated with a Buy at Seaport Global
Seaport Global analyst Corey Davis initiated Lipocine with a Buy and $10 price target. The analyst believes investors have given up on approval for Tlando given the complete response letter in 2016, the negative FDA AdCom, and current valuation. Davis does not expect FDA approval on the final FDA May 8 PDUFA, but thinks the agency may ask for ambulatory blood pressure study and study comparing "serum" testosterone to "plasma" testosterone in patients before and after dosing. If so, shares should react favorably and if the studies are positive, shares could react significantly.
02/27/18
EAMC
02/27/18
UPGRADE
EAMC
Buy
Lipocine upgraded to Buy from Hold at Empire
Empire analyst Cathy Reese upgraded Lipocine to Buy with a $21 price target, shares currently trade at $1.31, saying there is a high probability Tlando will gain approval, whether its on the May 8 PDUFA or once the once the blood pressure and collection test tube clinical data is reviewed sometime in 2018.
01/12/18
HCWC
01/12/18
NO CHANGE
Target $3
HCWC
Buy
Lipocine price target lowered to $3 from $10 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat lowered his price target for Lipocine to $3 saying the company is a "show me" story following the negative Tlando FDA panel vote. The analyst keeps a Buy rating on the shares.
01/11/18
LTCO
01/11/18
NO CHANGE
Target $11
LTCO
Buy
Lipocine price target lowered to $11 from $15 at Ladenburg
Ladenburg Thalmann analyst Matthew Kaplan cut his price target for Lipocine to $11 after an FDA committee voted 13 to 6 that the risk/benefit profile of Tlando is not currently supportive of approval for the treatment of hypogonadism. The analyst believes Tlando continues to represent an approvable product and that the blood pressure question can be addressed via a relatively a "relatively straightforward" study. Kaplan cites the likelihood of a complete response letter from the FDA for his target reduction but keeps a Buy rating on Lipocine shares.
NVO Novo Nordisk
$47.35

0.13 (0.28%)

12/11/18
JEFF
12/11/18
INITIATION
JEFF
Hold
Novo Nordisk assumed with a Hold at Jefferies
Jefferies analyst Peter Welford assumed coverage of Novo Nordisk with a Buy rating and DKK 285 price target. The analyst is positive on the European large-cap Pharma space "as it enters a period of sustained earnings momentum." He calls Novo his least preferred stock in the group.
01/02/19
JPMS
01/02/19
NO CHANGE
JPMS
JPMorgan adds Novo Nordisk to Analyst Focus List, removes Roche
JPMorgan analyst Richard Vosser added Novo Nordisk (NVO) to his firm's European Analyst Focus List while removing Roche (RHHBY).
11/26/18
PART
11/26/18
UPGRADE
PART
Buy
Novo Nordisk upgraded to Buy from Hold at Pareto
11/19/18
JPMS
11/19/18
UPGRADE
JPMS
Overweight
Novo Nordisk upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser upgraded Novo Nordisk to Overweight and raised his price target for the shares to 340 kroner from 290 kroner. The analyst sees the company's growth strengthening through 2019.

TODAY'S FREE FLY STORIES

SNAP

Snap

$6.19

0.455 (7.93%)

17:38
01/18/19
01/18
17:38
01/18/19
17:38
Periodicals
Snap exec fired due to undisclosed relationship with consultant, Cheddar says »

Snap's global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 05

    Feb

  • 03

    Mar

SSW

Seaspan

$9.16

0.16 (1.78%)

17:33
01/18/19
01/18
17:33
01/18/19
17:33
Syndicate
Breaking Syndicate news story on Seaspan »

Seaspan files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXT

Textron

$49.38

0.75 (1.54%)

17:30
01/18/19
01/18
17:30
01/18/19
17:30
Hot Stocks
Textron subsidiary awarded $439.56M government contract modification »

Bell Helicopter Textron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

TAC

TransAlta

$4.91

0.04 (0.82%)

17:28
01/18/19
01/18
17:28
01/18/19
17:28
Hot Stocks
Mangrove Partners reports 9.4% passive stake in TransAlta »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDS

Telephone and Data

$36.27

0.42 (1.17%)

17:27
01/18/19
01/18
17:27
01/18/19
17:27
Hot Stocks
Telephone and Data's Meyers sells 80,465 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWPH

GW Pharmaceuticals

$137.24

2.59 (1.92%)

17:03
01/18/19
01/18
17:03
01/18/19
17:03
Syndicate
Breaking Syndicate news story on GW Pharmaceuticals »

GW Pharmaceuticals files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCSC

Fibrocell Science

$2.03

0.03 (1.50%)

16:55
01/18/19
01/18
16:55
01/18/19
16:55
Syndicate
Breaking Syndicate news story on Fibrocell Science »

Fibrocell Science files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

, ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

16:49
01/18/19
01/18
16:49
01/18/19
16:49
Conference/Events
EnLink Midstream Partners to hold a special shareholder meeting »

Special Shareholder…

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

FDX

FedEx

$176.97

3.72 (2.15%)

16:49
01/18/19
01/18
16:49
01/18/19
16:49
Hot Stocks
FedEx establishes voluntary buyout program for U.S. workers »

FedEx said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 31

    Jan

  • 03

    Mar

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

, ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

16:48
01/18/19
01/18
16:48
01/18/19
16:48
Conference/Events
EnLink Midstream Companies to hold a special shareholder meeting »

Special Shareholder…

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

MKL

Markel

$1,067.03

13.52 (1.28%)

16:36
01/18/19
01/18
16:36
01/18/19
16:36
Hot Stocks
Markel says Anthony Belisle, Alissa Fredricks no longer with company »

Markel Corporation said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NILSY

Norilsk Nickel

$0.00

(0.00%)

16:35
01/18/19
01/18
16:35
01/18/19
16:35
Downgrade
Norilsk Nickel rating change  »

Norilsk Nickel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$130.65

1.54 (1.19%)

, ABBV

AbbVie

$89.51

2.28 (2.61%)

16:33
01/18/19
01/18
16:33
01/18/19
16:33
Hot Stocks
AbbVie: Phase 3 study of ibrutinib did not meet primary endpoint »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$130.65

1.54 (1.19%)

ABBV

AbbVie

$89.51

2.28 (2.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 27

    Jan

  • 28

    Jan

  • 18

    Feb

  • 18

    May

FOMX

Foamix

$3.70

-0.14 (-3.65%)

16:32
01/18/19
01/18
16:32
01/18/19
16:32
Conference/Events
Foamix to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

16:30
01/18/19
01/18
16:30
01/18/19
16:30
Options
Preliminary option volume of 26.9M today »

Preliminary option volume…

NBRV

Nabriva Therapeutics

$1.97

-0.01 (-0.51%)

16:27
01/18/19
01/18
16:27
01/18/19
16:27
Conference/Events
Nabriva Therapeutics to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 30

    Apr

VLRS

Volaris

$7.50

0.04 (0.54%)

16:21
01/18/19
01/18
16:21
01/18/19
16:21
Conference/Events
International Aviation Club to host monthly luncheon meeting »

Enrique Beltranena, CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
01/18/19
01/18
16:20
01/18/19
16:20
Options
Closing CBOE SPX and VIX Index summary for January 18th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
01/18/19
01/18
16:17
01/18/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
01/18/19
01/18
16:16
01/18/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTSV

Forty Seven

$14.48

-0.57 (-3.79%)

16:14
01/18/19
01/18
16:14
01/18/19
16:14
Conference/Events
Forty Seven to hold KOL breakfast symposium »

Key Opinion Leader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$302.26

-45.18 (-13.00%)

, WMT

Walmart

$97.75

1.01 (1.04%)

16:14
01/18/19
01/18
16:14
01/18/19
16:14
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks opened higher and…

TSLA

Tesla

$302.26

-45.18 (-13.00%)

WMT

Walmart

$97.75

1.01 (1.04%)

CVS

CVS Health

$65.49

2.13 (3.36%)

NFLX

Netflix

$339.20

-14.02 (-3.97%)

FB

Facebook

$150.01

1.77 (1.19%)

AAPL

Apple

$156.85

0.99 (0.64%)

QCOM

Qualcomm

$55.26

0.44 (0.80%)

FND

Floor & Decor

$31.99

2.34 (7.89%)

OZK

Bank OZK

$32.07

4.47 (16.20%)

VFC

VF Corp.

$82.39

9.135 (12.47%)

NLS

Nautilus

$7.00

-4.76 (-40.48%)

CASA

Casa Systems

$11.23

-3.17 (-22.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 24

    Jan

  • 24

    Jan

  • 29

    Jan

  • 30

    Jan

  • 30

    Jan

  • 25

    Feb

  • 25

    Feb

  • 03

    Mar

SNE

Sony

$50.08

0.58 (1.17%)

16:12
01/18/19
01/18
16:12
01/18/19
16:12
Periodicals
Sony Music ends working relationship with R. Kelly, Variety reports »

Sony Music has opted to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLD

Prologis

$64.58

0.53 (0.83%)

16:12
01/18/19
01/18
16:12
01/18/19
16:12
Hot Stocks
Prologis, Ivanhoe Cambridge form $880M joint venture in Brazil »

Prologis and Ivanhoe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CYDY

CytoDyn

$0.00

(0.00%)

16:10
01/18/19
01/18
16:10
01/18/19
16:10
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.